Retatrutide dosage is a topic of growing interest as this investigational triple agonist advances through clinical trials for obesity and type 2 diabetes. Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors — a mechanism that sets it apart from currently approved medicines such as semaglutide and tirzepatide. Phase 2 trial data have explored weekly subcutaneous doses ranging from 1 mg to 12 mg, administered via a gradual escalation schedule. However, retatrutide has not yet received regulatory approval from the MHRA, EMA, or FDA, meaning no licensed dosage currently exists. This article explains what the clinical evidence shows and what patients should know.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously, with Phase 2 trials using once-weekly subcutaneous doses of 1 mg to 12 mg; no licensed dosage has been established.

Retatrutide is an investigational medicine being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors:

• GLP-1 (glucagon-like peptide-1) – which reduces appetite and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) – which may enhance insulin secretion and has been suggested in early studies to support fat metabolism

• Glucagon receptor – which may increase energy expenditure and has been proposed to support fat breakdown in the liver, based on early pharmacological data

This triple mechanism distinguishes retatrutide from existing approved medicines such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist). By targeting all three receptors, retatrutide is designed to produce a more pronounced effect on body weight and blood glucose regulation, though whether this translates into superior long-term clinical outcomes remains to be confirmed in Phase 3 trials.

In a Phase 2 randomised controlled trial published in The New England Journal of Medicine (Jastreboff et al., 2023), participants without type 2 diabetes receiving the highest doses of retatrutide achieved mean body weight reductions of approximately 24% over 48 weeks. It is important to note that weight loss outcomes in participants with type 2 diabetes are typically more modest. These results, while promising, require confirmation in the ongoing Phase 3 programme before any conclusions about comparative efficacy can be drawn.

Regarding dosage, the Phase 2 trial investigated several dose levels administered as a once-weekly subcutaneous injection, ranging from 1 mg up to 12 mg per week, with a gradual escalation schedule. Higher doses were generally associated with greater weight loss but also a higher incidence of gastrointestinal side effects (Jastreboff et al., 2023). It is important to note that no licensed dosage has been established, as retatrutide has not yet received regulatory approval from any medicines authority. All dosing information currently available derives solely from controlled clinical research settings and must not be used as a guide for self-administration.

Side Effects and Safety Considerations

The most common side effects in trials were gastrointestinal — including nausea, vomiting, and diarrhoea — and were dose-dependent; elevated pulse rate was also observed due to retatrutide's glucagon receptor activity.

As with other medicines in the incretin-based drug class, the most commonly reported side effects of retatrutide in clinical trials were gastrointestinal in nature (Jastreboff et al., 2023). These included:

• Nausea (the most frequently reported adverse effect)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally dose-dependent, occurring more frequently and with greater severity at higher doses. In most participants, gastrointestinal symptoms were mild to moderate and tended to improve over time. Gradual dose escalation — as used in the clinical trials — appeared to help reduce the burden of these side effects. Patients should be aware that persistent vomiting or diarrhoea can lead to dehydration, and adequate fluid intake is important.

Retatrutide's glucagon receptor activity introduces some additional considerations compared to GLP-1-only agents. In the Phase 2 trial, elevated pulse rate was observed in some participants receiving retatrutide. Safety monitoring for cardiovascular parameters is conducted within the clinical trial setting; outside of trials, this medicine should not be used.

As a class effect observed with GLP-1 receptor agonists, there are precautionary concerns — based on animal studies — regarding thyroid C-cell tumours. This signal has not been confirmed in humans, but it is reflected in the prescribing information for approved GLP-1-based medicines such as semaglutide (see the UK Summary of Product Characteristics for Wegovy, available via the electronic Medicines Compendium). Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) were excluded from retatrutide trials.

Additionally, incretin-based therapies as a class carry a rare signal for pancreatitis, and rapid weight loss is associated with an increased risk of gallbladder disease (including gallstones). Whether these risks apply to retatrutide specifically is not yet established, as the full long-term safety profile remains unknown pending Phase 3 data.

Retatrutide trials excluded pregnant and breastfeeding individuals. As an investigational medicine, it must not be used outside of regulated clinical trial settings during pregnancy or breastfeeding.

If you experience suspected side effects from any medicine, these can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. The Yellow Card scheme also accepts reports of suspected product quality defects.

Because retatrutide is not yet approved, post-marketing surveillance data are not yet available. Patients should exercise caution regarding any products claiming to contain retatrutide that are sold outside of regulated clinical trial settings.

Retatrutide's Regulatory Status in the UK

Retatrutide has not been approved by the MHRA, EMA, or FDA and cannot legally be prescribed in the UK; Eli Lilly's Phase 3 TRIUMPH programme is ongoing before any regulatory submission.

As of the time of writing, retatrutide has not been approved for use in the United Kingdom. It has not received a marketing authorisation from the MHRA, nor has it been granted approval by the European Medicines Agency (EMA). In the United States, the FDA has also not yet approved retatrutide, though Eli Lilly has announced that it received Fast Track designation from the FDA for the treatment of obesity — a status that facilitates more frequent communication between the developer and the regulator to help expedite the review process.

Eli Lilly has announced that Phase 3 clinical trials (the TRIUMPH programme) are underway, investigating retatrutide across a broader population and over longer timeframes. These trials will provide the robust efficacy and safety data required for a formal regulatory submission. Ongoing trial registrations can be verified via the ClinicalTrials.gov registry. Until a marketing authorisation is granted, retatrutide cannot legally be prescribed or dispensed through NHS or private healthcare channels in the UK.

NICE (the National Institute for Health and Care Excellence) has not issued any guidance on retatrutide, as technology appraisals are only initiated once a medicine has received or is close to receiving regulatory approval. Patients and clinicians should be aware that purchasing retatrutide from unregulated online sources carries significant safety risks, including the possibility of receiving counterfeit, contaminated, or incorrectly dosed products.

The MHRA actively monitors and takes enforcement action against the unlicensed supply of prescription-only medicines. To report suspected illegal online sales or unlicensed supply of medicines, use the MHRA's enforcement reporting route at gov.uk/report-problem-medicine-medical-device — this is distinct from the Yellow Card scheme, which is for reporting suspected side effects or product quality defects.

Anyone considering participation in a clinical trial involving retatrutide should seek information through official channels such as the NIHR 'Be Part of Research' website (bepartofresearch.nihr.ac.uk) or the ClinicalTrials.gov registry.

Talking to Your Doctor About New Weight Loss Medicines

Patients interested in new weight loss treatments should speak to their GP about currently approved options such as semaglutide (Wegovy) or enquire about clinical trial eligibility through the NIHR 'Be Part of Research' website.

It is entirely understandable to feel curious — or even hopeful — about emerging treatments such as retatrutide, particularly if you have struggled with obesity or weight-related health conditions for some time. However, it is essential to discuss this topic with your GP or a specialist rather than attempting to source or use unlicensed medicines independently.

When speaking with your doctor, it may be helpful to:

• Share your weight management history, including previous treatments, lifestyle interventions, and any underlying conditions such as type 2 diabetes, hypertension, or sleep apnoea

• Ask about currently approved options, such as orlistat (available on the NHS; see the NHS orlistat page for eligibility and guidance), or GLP-1-based therapies such as semaglutide 2.4 mg (Wegovy®), which has received MHRA approval and a NICE Technology Appraisal recommendation (NICE TA875) for use in adults with a BMI of 35 kg/m² or above (or 30–34.9 kg/m² in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service

• Enquire about clinical trial eligibility, if you are interested in accessing investigational medicines through a regulated research pathway — your GP or specialist can advise, and you can search for trials via the NIHR 'Be Part of Research' website or ClinicalTrials.gov

• Discuss realistic expectations, as even the most effective weight loss medicines work best alongside dietary changes, increased physical activity, and behavioural support

Your GP can refer you to a specialist weight management service if appropriate. In England, these are typically structured as Tier 3 (specialist multidisciplinary services) or Tier 4 (bariatric surgery services), with referral criteria that may vary by Integrated Care System (ICS). These services offer multidisciplinary support and, where clinically indicated, access to pharmacological treatments, in line with NICE obesity guidance (NICE CG189 and quality standard QS127, alongside relevant technology appraisals).

If you encounter websites or social media content promoting retatrutide for sale, do not purchase or use these products. Report suspected illegal online sales or unlicensed supply to the MHRA via gov.uk/report-problem-medicine-medical-device. If you experience a suspected side effect from any medicine, report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Your safety is the priority, and the most effective path to accessing new treatments remains through your healthcare team and properly regulated clinical channels.

Frequently Asked Questions